Covimro

Covimro is a UK private biotech and orthomolecular healthcare company developing virus-agnostic antiviral treatment models aimed primarily at coronavirus and other viral infections. The company presents a three-part product architecture designed to disrupt viral membranes, interfere with spike-mediated attachment and fusion, and inhibit viral replication through 3CL protease targeting. Its public materials describe preclinical and pilot study work spanning SARS-CoV-2, influenza A, and lentiviral/HIV models, with research conducted alongside university and external research partners. Covimro positions its technology for potential commercialization across consumer, OTC, and pharmaceutical channels. The company appears to remain an early-stage, privately held, active business rather than a clinical-stage drug developer.